Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reproxalap - Aldeyra Therapeutics

Next Previous
Drug Profile

Reproxalap - Aldeyra Therapeutics

Alternative Names: ADX 102; NS 2; NS-2-Aldeyra

Latest Information Update: 01 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aldeyra Therapeutics
  • Class Anti-inflammatories; Chlorinated hydrocarbons; Eye disorder therapies; Quinolines; Skin disorder therapies; Small molecules
  • Mechanism of Action Malondialdehyde inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sjogren-Larsson syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Dry eyes
  • Phase III Allergic conjunctivitis
  • Preclinical SARS-CoV-2 acute respiratory disease
  • Suspended Sjogren-Larsson syndrome
  • No development reported Contact dermatitis; Inborn error metabolic disorders; Inflammation; Mucositis
  • Discontinued Uveitis

Most Recent Events

  • 28 Mar 2024 Aldeyra Therapeutics plans to files NDA resubmission for Dry eyes in USA in the second half of 2024
  • 23 Feb 2024 Efficacy data from the phase III INVIGORATE and INVIGORATE 2 trial in Allergic conjunctivitis presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2024)
  • 27 Nov 2023 Aldeyra Therapeutics plans to launch Reproxalap for Dry eyes
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top